Annals of Hematology

Papers
(The TQCC of Annals of Hematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
A case of acute promyelocytic leukemia with pericardial effusion successfully managed with colchicine during ATO administration63
Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate53
A new case of Bicêtre hemoglobin in an adult male: clinical observations over a period of four years50
Refractory hepatosplenic T-cell lymphoma was successfully treated with salvage allogeneic hematopoietic stem cell transplantation combined with enhanced myeloablative preconditioning46
Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis44
Real-life use of mTOR inhibitor-based therapy in adults with autoimmune cytopenia highlights strong efficacy in relapsing/refractory multi-lineage autoimmune cytopenia41
Correction to: Hemophagocytic lymphohistiocytosis in HIV-associated lymphoproliferative disorders39
Efficacy and safety of olverembatinib as maintenance therapy after allogeneic hematopoietic cell transplantation in Philadelphia chromosome–positive acute lymphoblastic leukemia39
Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study38
Causes of death and treatment-related mortality in newly diagnosed childhood acute lymphoblastic leukemia treatment with Chinese Children’s Cancer Group study ALL-201537
Sufficient vitamin D is favorable for children with persistent and chronic immune thrombocytopenia36
Renin-angiotensin inhibitors reduce thrombotic complications in Essential Thrombocythemia and Polycythemia Vera patients with arterial hypertension35
Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma34
Intramural esophageal hematoma precipitated by acquired factor XI deficiency in a patient with relapsed T cell prolymphocytic leukemia after allogeneic hematopoietic cell transplantation31
Genetic variability profiling of the p53 signaling pathway in chronic lymphocytic leukemia. Individual and combined analysis of TP53, MDM2 and NQO1 gene variants30
Advances in the ocular complications after hematopoietic stem cell transplantation29
The presence of idiopathic thrombocytopenic purpura and incidence of acute non-ST elevation myocardial infarction29
CML in the very elderly: the impact of comorbidities and TKI selection in a real-life multicenter study28
Clonal evolution analysis of a rare acute promyelocytic leukemia patient transforming from essential thrombocythemia27
Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group26
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease26
Maternal factors associated with iron deficiency without anaemia in early pregnancy: ECLIPSES study25
Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma23
Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments23
Detection of circulating tumor DNA in cerebrospinal fluid prior to diagnosis of spinal cord lymphoma by flow cytometric and cytologic analyses21
Analysis of incidence and risk factors of the multidrug resistant gastrointestinal tract infection in children and adolescents undergoing allogeneic and autologous hematopoietic cell transplantation: 20
JAK2V617F mutation in patients with β-thalassemia disease: prevalence and clinical characteristics20
Refractory pure red cell aplasia associated with T-cell large granular lymphocyte leukemia treated by ruxolitinib20
Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data20
Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experienc20
Successful treatment of hairy cell leukemia variant with obinutuzumab20
Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: National Cancer Database analysis19
Symposium Proceedings of the international symposium ACUTE LEUKEMIAS XIX (ISALXIX), Munich March 16–19, 202519
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience19
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives19
Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade18
A randomized controlled trial of thrice-weekly versus thrice-daily oral ferrous fumarate treatment in adult patients with iron-deficiency anemia18
Radiotherapy alone with curative intent in a case of limited-stage extranodal NK/T-cell lymphoma nasal type: a case report and review of the literature18
Activity of trametinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory RAS pathway-mutated hematologic malignancies18
Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrosp17
A nomogram model for predicting the efficacy of cyclosporine in patients with pure red cell aplasia17
Paroxysmal nocturnal haemoglobinuria in pregnancy–a systematic review with meta analysis16
Treatment patterns and healthcare resource utilization in ruxolitinib-treated patients with myelofibrosis with and without anemia: a real-world analysis16
Molecular profiling of cell-free DNA from classic Hodgkin lymphoma patients identifies potential prognostic clusters and corresponds with disease dynamics16
Nomogram for predicting survival of patients with diffuse large B-cell lymphoma16
Impact of induction regimens on stem cell mobilization yields in newly diagnosed multiple myeloma16
Global, regional and national temporal trends in incidence and mortality of non-Hodgkin lymphoma from 1992 to 2021: an age-period-cohort analysis15
Correction to: Delphi consensus recommendations on treatment for advanced-stage marginal zone lymphoma in South Korea15
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts15
Copy number alterations in pediatric B-cell precursor acute lymphoblastic leukemia patients and their association with patients’ outcome15
Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials14
Absence of blood donors’ anti-SARS-CoV-2 antibodies in pre-storage leukoreduced red blood cell units indicates no role of passive immunity for blood recipients14
Ferroptosis: a new target for iron overload-induced hemophilic arthropathy synovitis14
Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience14
Post-transplant lymphoproliferative disease of two different histological types14
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia14
Leukemia cutis in accelerated chronic lymphocytic leukemia: successful treatment with venetoclax and rituximab14
Circulating tumor DNA assisting lymphoma genetic feature profiling and identification14
Cerebral infarction in a patient with inhibitor-positive hemophilia B treated with plasma-derived factor VIIa and factor X mixture13
Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs13
Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia13
Adipocyte fatty acid-binding protein (FABP4) as a potential biomarker for predicting metabolically driven low-grade and organ damage in thalassemia syndromes13
TGFBI regulates the TGF-β pathway to affect the malignant progression and cisplatin sensitivity in diffuse large B-cell lymphoma13
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes12
Detection of pulse rate elevation by Apple Watch in a patient with bronchiolitis obliterans syndrome after allogeneic stem cell transplantation12
Non-Hodgkin lymphomas and ionizing radiation: case report and review of the literature12
Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews12
Advances in epigenetic therapies for B-cell non-hodgkin lymphoma12
Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)12
Sex differences in fatigue and symptoms of anemia in relation to hemoglobin level in hospitalized patients12
Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma12
A novel WNK1::PDGFRB fusion gene in myeloid neoplasm with eosinophilia: a case report12
Radiation hazards of the Ukraine nuclear power plants: how can international blood and marrow stem cell transplant societies help?12
Bilateral deafness in NK/T-cell lymphoma: EBV DNA prevailed over magnetic resonance imaging12
Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenström Macroglobulinemia: a monocentric experience12
Mutational heterogeneity in large B-cell lymphoma: insights from paired biopsies12
Immune profiling of patients with extranodal natural killer/T cell lymphoma treated with daratumumab12
Acute promyelocytic leukemia derived extracellular vesicles conserve PML-RARα transcript from storage-inflicted degradation: a stable diagnosis tool in APL patients11
Specificity protein 1/3 regulate T-cell acute lymphoblastic leukemia cell proliferation and apoptosis through β-catenin by acting as targets of miR-495-3p11
Correction to: Potential risk factors for the development from immune thrombocytopenia to systemic lupus erythematosus: a case–control study in Chinese children11
Correction to: Spanish registry of hemoglobinopathies and rare anemias (REHem- AR): demographics, complications, and management of patients with β-thalassemia11
Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review11
Management of latent tuberculosis infection (LTBI) in adult patients with newly diagnosed acute leukemia: results of a survey among Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Inf11
Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report11
Efficacy and safety of new-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia/small lymphocytic lymphoma: a systematic review and meta-analysis11
Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm11
Critical risk factors analysis of infection-associated hemophagocytic lymphohistiocytosis in children11
Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry11
Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab11
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome11
Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia11
CD20/CD79a/PAX5/CD3-negative post-transplant lymphoma with aberrant actin and desmin co-expression—a potential differential diagnostic pitfall between PTLD and PTSMT11
The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria11
Efficacy and safety of allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients aged > 65 years with unfavorable cytogenetics11
Identification of CD105 (endoglin) as novel risk marker in CLL11
A multicentre ambispective observational study into the incidence and clinical management of aplastic anaemia in Spain (IMAS study)11
Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment10
Clinical prognostic value of different NPM1 mutations in acute myeloid leukemia patients10
Prognostic significance of early nk cell recovery in pediatric t-cell replete allogeneic hematopoietic stem cell transplantation10
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute myeloid leukemia: a real-world analysis10
Life-threatening paraneoplastic cardiovascular events in ALK-positive anaplastic large cell lymphoma10
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by ‘Rete Ematol10
Bisphosphonate use for glucocorticoid-induced osteoporosis in older patients with immune thrombocytopenia: a clinical perspective10
Identification of a novel cryptic variant chromosomal rearrangement involving 9q34, 22q11.2, and 5q22 resulting in ins(9;22) and t(5;22) in chronic myeloid leukemia: a case report10
Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms10
Clinical features and outcomes of 17 children with systemic juvenile xanthogranuloma (sJXG) including five complicated with hemophagocytic lymphohistiocytosis (HLH)10
Validity of the criteria for clinical transformation of follicular lymphoma: analysis of a mostly biopsied cohort10
Epigenetically dysregulated NOTCH-Delta-HES signaling cascade can serve as a subtype classifier for acute lymphoblastic leukemia10
Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes10
Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL)10
An unexpected find of multifocal extranodal marginal zone lymphoma9
Real-world challenges in the management of acute myeloid leukemia: a single-center experience from North India9
Pseudothrombocytopenia, beyond a laboratory phenomenon: study of 192 cases9
Acute liver failure associated with human adenovirus infection after allogeneic hematopoietic stem cell transplantation9
Are accessory spleen screening and resection in refractory immune cytopenia an effective strategy or a waste of resources?9
Chronic neutrophilic leukemia with JAK2 mutation: is it true chronic neutrophilic leukemia?9
Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma9
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma9
Sickle cell disease and opioid overdose outcomes in the United States: a nationwide analysis9
Adult type I Gaucher disease with splenectomy caused by a compound heterozygous GBA1 mutation in a Chinese patient: a case report9
The roles of ubiquitination in AML9
Next-generation sequencing redefines the diagnosis of triple-negative myeloproliferative neoplasms9
The experience of diagnosis and treatment for TAFRO syndrome9
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial9
ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies9
Management of paroxysmal nocturnal hemoglobinuria with low-level hemolysis in pregnancy– a report of two cases9
Zebrafish modeling of atypical PML-RARA isoform from acute promyelocytic leukemia patient and its implications for clinical treatment9
COVID-19: impact of vaccination in myeloma patients9
Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Beijing since December 2022: a retrospective study at a National Clinical Research Cen8
Platelet recovery with ibrutinib therapy in patient with treatment-refractory immune thrombocytopenia8
Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use8
In-depth molecular analysis of lymphomas with lymphoplasmacytic differentiation may provide more precise diagnosis and rational treatment allocation8
Interim PET in follicular lymphoma: more patience, please8
A new score for predicting intracranial hemorrhage in patients using antiplatelet drugs8
Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database8
Characteristics of inpatients with newly diagnosed multiple myeloma in hematology, nephrology, and orthopedic departments8
Overcoming right heart failure through successful treatment of cardiac dominant diffuse large B-cell lymphoma: a case report8
A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate8
No aggravation of congenital thrombotic thrombocytopenic purpura by mRNA-based vaccines against COVID-19: a Japanese registry survey8
Optimal dosage of rituximab for children with Burkitt lymphoma8
A comparative study of platelet storage lesion in platelet-rich plasma under cryopreservation8
Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)8
Bibliometric analysis of worldwide research on Polycythemia Vera in the 21st century8
Post-transplant transient abnormal myelopoiesis evolving from a GATA1 mutant clone in umbilical cord blood8
Liquid biopsies of plasma and cerebrospinal fluid are useful for detection of intravascular lymphoma with central nervous system symptoms alone8
Safety of romiplostim administered immediately after cord-blood transplantation: a phase 1 trial8
Is comprehensive geriatric testing guiding in the identification of multiple myeloma patients who are candidates for autologous stem cell transplantation? A prospective analysis8
Vaccine-induced pseudothrombocytopenia after Ad26.COV2.S vaccination8
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience8
Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors8
Evaluation of the cachexia index using a bioelectrical impedance analysis in elderly patients with non-Hodgkin’s lymphoma: A single-center prospective study8
Incidence and reasons for discontinuation of first-line therapy in patients with multiple myeloma: results from a historical cohort, Brazil 2009–20208
Severe platelet transfusion refractoriness due to anti-HPA-5a antibody during induction chemotherapy for acute promyelocytic leukemia8
Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia8
Blinatumomab-induced macrophage activating syndrome (MAS) in adult with B-cell acute lymphoblastic leukemia (B-ALL)7
Anticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis7
Co-occurrence of Erdheim-Chester disease and clonally evolving acute myeloid leukemia with FLT3-ITD and PTPN11 mutations7
Prognostic factors in patients with secondary hemophagocytic lymphohistioc ytosis in a Chinese cohort7
Molecular characteristics of hereditary red blood cell membrane disorders in Thailand: a multi-center registry7
Comparable clinical outcomes of haploidentical hematopoietic stem cell transplantation in patients with hepatitis-associated aplastic anemia and non-hepatitis-associated aplastic anemia7
Case report:Clinical manifestations and therapeutic options following rhTPO-induced neutralizing antibody production in a child with immune thrombocytopenia7
Association between N-acetylcysteine treatment and in-hospital mortality in adult patients with acquired thrombotic thrombocytopenic purpura: a cohort study7
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report7
Benefit of high-dose idarubicin as induction therapy in acute myeloid leukemia: a prospective phase 2 study7
Immune reconstitution and survival of patients with parvovirus B19 related pure red cell aplasia after haplo-PBSCT7
The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia7
Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia7
Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype MDS patients7
Prognostic value of metabolic tumor volume of extranodal involvement in diffuse large B cell lymphoma7
Magnitude of cumulative iron overload correlates with the severity of anemia in untreated non-transfusion-dependent β-thalassemia7
An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma7
Association between low incidence of TP53 mutations and reduced early relapse rates in Uygur DLBCL7
Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia7
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory7
Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings7
Enhancing outcomes of childhood acute lymphoblastic leukemia in workplace diversity in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group7
Cord blood resilience in a patient with relapsing Ph + B lymphoblastic acute leukemia after hematopoietic stem cell transplantation7
Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants7
Mendelian randomization of circulating proteome identifies IFN-γ as a druggable target in aplastic anemia7
2-[18]F FDG PET/CT dissemination features in adult burkitt lymphoma Are predictive of outcome7
miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia7
Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia7
Development of disseminated intravascular coagulation in asymptomatic leukemic non-nodal mantle cell lymphoma7
Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab7
Prognostic factors for patients with hematologic malignancies admitted to the intensive care unit: is allogeneic transplantation still a risk factor?7
Validation of a Stenotrophomonas maltophilia bloodstream infection prediction score in the hematologic malignancy population7
Association of inflammation and abnormal lipid metabolism with risk of thrombosis and thrombosis progression in patients with polycythemia vera: a retrospective study7
Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study7
VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management7
Analysis of PROS1 mutations and clinical characteristics in three Chinese families with hereditary protein S deficiency7
Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study7
Donor’s age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience7
Analysis of Wilms’ tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed7
Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study7
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study6
Real-world experience of anti-D immunoglobulin in immune thrombocytopenia6
Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide6
Investigation of TSRP reverses imatinib resistance through the PI3K / Akt pathway in chronic myeloid leukemia6
Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma6
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabru6
A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM16
Prognostic impact of Auer rods for cytoreductive chemotherapy and myeloablative allogeneic stem cell transplantation in adult patients with myelodysplastic syndrome with excess blasts-26
Sickle cell disease and acute leukemia: one case report and an extensive review6
Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives6
T(11;14) with multiple myeloma: Standard risk survival but slow and poor response6
Alectinib maintenance therapy following cord blood transplantation for relapsed pediatric anaplastic large cell lymphoma with central nervous system involvement6
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma6
Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients6
L-DEP regimen is effective as an initial therapy for adult EBV-HLH6
Clinical effect of CALR allele burden in patients with essential thrombocythemia6
Mass cytometry analysis identifies T cell immune signature of aplastic anemia and predicts the response to cyclosporine6
The added value of digital morphological analysis in the evaluation of peripheral blood films: the report of an UKNEQAS external quality assessment sample6
Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study6
How to combine multiple tools for the genetic diagnosis work-up of pediatric B-cell acute lymphoblastic leukemia 6
Correction to: One disease, two faces: clonally-related AML and MPDCP with skin involvement6
Two cases of refractory IgG4-related disease successfully treated with tocilizumab6
Incidence and impact of Epstein-Barr virus events in the early phase after allogeneic hematopoietic cell transplantation6
Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials6
Development and validation of an early mortality risk model for pediatric hemophagocytic lymphohistiocytosis: a comparison with HScore, PELOD-2, P-MODS, and pSOFA6
A synchronous therapy with daratumumab and enzymatic replacement therapy (ERT) in a patient with Gaucher disease and multiple myeloma6
CXC chemokine ligand 13 and galectin-9 plasma levels collaboratively provide prediction of disease activity and progression-free survival in chronic lymphocytic leukemia6
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey6
Clinical features and outcomes in large granular lymphocyte leukemia − associated pure red cell aplasia with STAT3 mutation6
Broadening perspectives: redefining the role of obesity in ITP6
Expression of the immune checkpoint receptors CTLA-4, LAG-3, and TIM-3 in β-thalassemia major patients: correlation with alloantibody production and regulatory T cells (Tregs) phenotype6
Impact of antithymocyte globulin on blood cyclosporin A levels in aplastic anemia patients6
Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation6
Recent advances in CD5+ diffuse large B-cell lymphoma6
A case report of dyskeratosis congenita caused by a novel TERC mutation6
Vincristine therapy for severe and refractory immune thrombocytopenia following COVID-19 vaccination6
Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians6
Rhabdomyolysis induced by nelarabine6
Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study6
Development and validation of nomogram prognostic model for predicting OS in patients with diffuse large B-cell lymphoma: a cohort study in China6
Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation6
Hemolytic anemia in COVID-196
Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases6
N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study6
Successful treatment with oseltamivir phosphate in children with ITP who failed first-line therapy: a case series report6
Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation6
A case of visual impairment due to HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation in childhood acute myeloid leukemia-M2 subtype6
The effects of complement-independent, autoantibody-induced apoptosis of platelets in immune thrombocytopenia (ITP)6
FLOT1 knockdown inhibits growth of AML cells through triggering apoptosis and pyroptosis6
A predictive diagnostic model for refractory diffuse large B-cell lymphoma: a single-center retrospective cohort study6
MALAT1/miR-582-5p/GALNT1/MUC1 axis modulates progression of AML leukemia stem cells by regulating JAK2/STAT3 pathway6
Impact of protein-energy malnutrition on outcomes of patients with sickle cell disease: an analysis of the National inpatient sample6
Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease6
Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)6
The incidence and characteristics of VTE within 100 days of CAR T-cell therapy5
Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course5
0.082113027572632